New Delhi: Wɔ Fresenius Medical Care nyansahyɛ bi ho mmuaema mu no, Central Drugs Standard Control Organization (CDSCO) no Specialty Expert Committee (SEC) akamfo akyerɛ adwumakuw no sɛ wɔmfa ntease a enti wɔpene so no nka ɔfã III ayaresabea sɔhwɛ ho nsɛm a ɛfa calcium chloride dihydrate ne aguadi akyi nhwehwɛmu ho nsɛm a efi aman a wɔapene so no ho nkɔma na wonsusuw ho bio.
Adwumakuw no adi kan de akwammisa krataa akɔma sɛ wɔnyɛ na wɔtɔn calcium chloride dihydrate solution a ne dodow yɛ 100 mmol/L, a wɔde yɛ “calcium a wɔde si ananmu ayaresa wɔ adwene mu aduru a wɔde si ananmu a ɛkɔ so (CRRT), a wɔde kɔ so yɛ aduru a ɛnyɛ adwuma yiye (da biara da) a wɔde citrate anticoagulation yɛ mu.Aduru no fata ma mpanyimfo ne mmofra” na ɔkaa nea enti a wɔayi wɔn afi ɔfã III ne ɔfã IV ayaresabea sɔhwɛ ahorow mu.
Boayikuw no kae sɛ wɔapene aduru no so wɔ Europa aman te sɛ Portugal, United Kingdom, Brazil, Switzerland, France ne Denmark.
Calcium chloride dihydrate a wɔabom ayɛ no ne CaCl2 2H2O, a ɛyɛ calcium chloride a nsuo molecule mmienu wɔ calcium chloride unit biara mu. Ɛyɛ ade fitaa a ɛte sɛ ahwehwɛ, ɛtumi nwura nsuo mu ntɛm na ɛyɛ nsuo, kyerɛ sɛ ɛtumi twetwe nsuo a ɛfiri mframa mu.
Calcium chloride dihydrate yɛ aduru a wobetumi de adi dwuma sɛ aduru a wɔde bɛpete chitin bere a wɔapete wɔ methanol mu no. Ɛdi dwuma titiriw wɔ chitin ahwehwɛ nhyehyɛe a ɛbubu mu na ɛwɔ dwumadie ahodoɔ pii wɔ nnuruyɛ mu.
Wɔ SEC Nephrology nhyiamu a wɔyɛɛ no ​​May 20, 2025 no, bagua no hwɛɛ nyansahyɛ bi a wɔde too gua sɛ wɔbɛpene so sɛ wɔbɛyɛ na wɔatɔn 100 mmol/L calcium chloride dihydrate infusion solution a wɔde bedi dwuma wɔ “calcium a wɔde si ananmu aduruyɛ mu wɔ adwene mu aduru a wɔde si ananmu a ɛkɔ so (CRRT), plasma a ɛnyɛ adwuma yiye (da biara da) dialysis a ɛkɔ so (SLEDD), ne ayaresa a wɔde sesa no mu (TPE) a wɔde citrate anticoagulation ahyɛ mu ma Wɔakyerɛ aduru no wɔ mpanyimfo ne mmofra mu” na ɛde ntease mae sɛ wɔayi wɔn afi ɔfã III ne IV ayaresabea sɔhwɛ ahorow mu.
Wɔ nkɔmmɔbɔ a ɛkɔ akyiri akyi no, boayikuw no kamfoo kyerɛe sɛ wɔmfa nea wobegyina so apene so, ne ɔfã III ayaresabea sɔhwɛ ho nsɛm ne aguadi akyi nhwehwɛmu ho nsɛm a efi aman a wɔapene aduru no so no nkɔma boayikuw no ma wonsusuw ho bio.
Kenkan nso: CDSCO Kuw no Apene Nkyerɛwde a Wɔayɛ no Foforo so ama Sanofi Myozyme, Wɔsrɛ sɛ Wɔhwehwɛ Mmara mu Nhwehwɛmu
Oduruyɛfo Divya Kolin yɛ obi a wawie PharmD a ɔwɔ ayaresabea ne ayaresabea osuahu kɛse na ɔwɔ nhwehwɛmu ne ayaresa ho nimdeɛ a ɛkyɛn so. Wayɛ adwuma nso sɛ oncology nnuruyɛfo wɔ oncology dwumadibea wɔ Mysore Medical College and Research Institute. Mprempren ɔreyɛ n’adwuma wɔ ayaresabea nhwehwɛmu ne ayaresabea data sohwɛ mu. Ɔne Medical Dialogue ayɛ adwuma fi January 2022.
       Dr Kamal Kant Kohli, MBBS, MD, CP, is a thoracic specialist with over 30 years of experience and specializes in clinical writing. He joins Medical Dialogues as the Editor-in-Chief of Medical News. Apart from writing articles, as the Editor, he is responsible for proofreading and reviewing all medical content published in Medical Dialogues, including content from journals, research papers, medical conferences, guidelines, etc. Email: drkohli@medicaldialogues.in Contact: 011-43720751
ABYSS nhwehwɛmu no hui sɛ beta-blockers a wogyaee wɔ koma ntini mu yare akyi no ma mogya mmoroso, koma bɔ, ne koma ne ntini mu nsɛmmɔnedi kɔɔ soro: ...